Long-term safety and effectiveness of tulisokibart for Crohn's or colitis
Treatments studied
Part of Digestive system clinical trials.
This study gives tulisokibart to people who already took part in an earlier trial for Crohn's disease or ulcerative colitis and are still benefiting from it. The goal is to see how safe and effective the medicine is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in a previous study of tulisokibart for Crohn's disease or ulcerative colitis.
- Your doctor agrees that tulisokibart is helping you and you should keep taking it.
- If you are able to become pregnant, you are not pregnant or breastfeeding, and you use birth control or do not have penis-vagina sex.
- You did not stop the study drug early in your previous study.
- You did not take any medications that were not allowed during your previous study.
- You are not allergic to tulisokibart or any of its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new medicines for people with moderate to severe ulcerative colitis who haven't found relief with standard treatments. Participants will receive one of several investigational drugs (these are not yet approved and are being studied for safety and tolerability). The goal is to see if the drugs are safe and if they might help control symptoms.
This study tests a new investigational drug (called LMT503) for the first time in humans, in healthy volunteers. It is a phase 1 trial that will look at how the body processes the drug and its safety, including how it behaves in the blood. The trial involves taking the drug once (single dose) or multiple times over several days, with close monitoring by the research team.
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
This trial tests a new drug called tulisokibart for people with psoriatic arthritis (PsA), a condition that causes joint pain and skin plaques. It may help if you have not tried certain biologic medications or if they did not work well.
This study tests a new medicine called Tulisokibart for people with a type of inflammatory arthritis that affects the spine and pelvic joints, specifically when X-rays show changes. The goal is to see if it can reduce symptoms like pain and stiffness.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.